Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Subcutaneous LY2439821 in Japanese Rheumatoid Arthritis Patients on Methotrexate
jRCT2080221280Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ixekizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company.
02
Drugs
ixekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080221280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221280.